Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.59 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14070292 | 0.92 | BRAF (0.48) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14070075 | 0.89 | BTK (0.49) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14070276 | 0.86 | BRAF (0.44) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14070199 | 0.86 | BRAF (0.44) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14070219 | 0.86 | BTK (0.56) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14070270 | 0.85 | KDM4E (0.46) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14069748 | 0.85 | BTK (0.47) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14069575 | 0.85 | BTK (0.48) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14070291 | 0.85 | BTK (0.44) | BRAFBTKLCKINSRLYN | |
| SCHEMBL14070217 | 0.85 | BTK (0.44) | BRAFBTKLCKINSRLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008112695-A2 | PYRAZOLO [3,4-D] PYRIMIDINES AND 1, 2, 5, 6-TETRAAZA- AS- INDACENES AS PROTEIN KINASE INHIBITORS FOR CANCER TREATMENT | IRM LLC (BM) | 2008-09-18 | — | — | WO | disclosed |